Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major

Blood Cells, Molecules, and Diseases

Volumn 51, Issue 2, 2013, Pages 85-88

  Filosa, Aldo ^a   Vitrano, Angela ^b   Rigano, Paolo ^c   Calvaruso, Giuseppina ^c   Barone, Rita ^c   Capra, Marcello ^d   Cuccia, Liana ^d   Gagliardotto, Francesco ^d   Pitrolo, Lorella ^c   Prossomariti, Luciano ^a   Casale, Maddalena ^a   Caruso, Vincenzo ^e   Gerardi, Calogera ^f   Campisi, Saveria ^g   Cianciulli, Paolo ^h   Rizzo, Michele ⁱ   D'Ascola, Giuseppe ^j   Ciancio, Angela ^k   Maggio, Aurelio ^c  

^a CARDARELLI HOSPITAL   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c UOC Ematologia II con Talassemia   (Italy)

^d ARNAS Civico   (Italy)

^e ARNAS Garibaldi   (Italy)

^f AOOCR Sciacca ^*  (Italy)

^g UOS Centro Microcitemia   (Italy)

^h AO S Eugenio   (Italy)

ⁱ UOC Ematologia   (Italy)

^j Centro Microcitemia   (Italy)

^k Ospedale Civile Madonna delle Grazie   (Italy)

more..

Author keywords

Chelation; Deferiprone; Deferoxamine; Echocardiography; Left ventricular ejection fraction (LVEF); Thalassemia major

Indexed keywords

ANTIOXIDANT; DEFERIPRONE; DEFEROXAMINE;

ADULT; ARTICLE; CELL COUNT; CELL FUNCTION; CHELATION THERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MECHANISM; DRUG TRANSPORT; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MITOCHONDRION; HEART MUSCLE CELL; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; MONOTHERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THALASSEMIA MAJOR; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; BETA-THALASSEMIA; DEFEROXAMINE; FEMALE; HEART DISEASES; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; PYRIDONES; RETROSPECTIVE STUDIES; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT; YOUNG ADULT;

EID: 84878394880     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2013.04.002     Document Type: Article

References (28)

1. Higgs D.R., Engel J.D., Stamatoyannopoulos G. Thalassemia. Lancet 2012, 373-383.
2. Modell B., Khan M., Darlison M. Survival in β-thalassaemia major in the UK: data from the UK thalassaemia register. Lancet 2000, 355:2051-2052.
3. Borgna-Pignatti C., Rugolotto S., De Stefano S.P., Zhao H., Del Vecchio G.C., Romeo M.A., Forni G.L., Gamberini M.R., Ghilardi R., Piga A., Cnaan A. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004, 89(10):1187-1193.
4. Anderson L.J., Holden S., Davis B., Prescott E., Charrier C.C., Bunce N.H., Firmin D.N., Wonke B., Porter J., Walker J.M., Pennell D.J. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur. Heart J. 2001, 22:2171-2179.
5. Modell B., Khan M., Darlison M., Westwood M.A., Ingram D., Pennell D.J. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J. Cardiovasc. Magn. Reson. Sep 25 2008, 10:42.
6. Cunningham M.J., Macklin E.A., Neufeld E.J., Cohen A.R. Complications of beta-thalassemia major in North America. Blood 2004, 104(1):34-39.
7. Borgna-Pignatti C., Cappellini M.D., De Stefano P., Del Vecchio G.C., Forni G.L., Gamberini M.R., Ghilardi R., Piga A., Romeo M.A., Zhao H., Cnaan A. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006, 107(9):3733-3737. (2006).
8. Maggio A., Vitrano A., Lucania G., Capra M., Cuccia L., Gagliardotto F., Pitrolo L., Prossomariti L., Filosa A., Caruso V., Gerardi C., Campisi S., Cianciulli P., Rizzo M., D'Ascola G., Ciancio A., Di Maggio R., Calvaruso G., Pantalone G.R., Rigano P. Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients. Am. J. Hematol. 2012, 87:732-733.
9. Pepe A., Lombardi M., Positano V., Cracolici E., Capra M., Malizia R., Prossomariti L., De Marchi D., Midiri M., Maggio A. Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2* Eur. J. Haematol. 2006, 76(3):183-192.
10. Pennell D.J., Berdoukas V., Karagiorga M., Ladis V., Piga A., Aessopos A., Gotsis E.D., Tanner M.A., Smith M.A.G.C., Westwood B.Wonke, Galanello R. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006, 107(9):3738-3744.
11. Schiller N.B., Shah P.M., Crawford M., De Maria A., Devereux R., Feigenbaum H., Gutgesell H., Reichek N., Sahn D., Schnitteger I. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards. Subcommittee on quantitation of Two-Dimensional Echocardiograms. J. Am. Soc. Echocardiogr. 1989, 2(5):358-367.
12. Cogliandro T., Derchi G., Mancuso L., Pannone B., Pepe A., Pili M., Bina P., Cianciulli P., De Sanctis V., Maggio A. Guideline recommendations for heart complications in thalassemia major. J. Cardiovasc. Med. (Hagerstown) 2008, 9:515-525.
13. Di Marco V., Capra M., Angelucci E., Borgna-Pignatti C., Telfer P., Harmatz P., Kattamis A., Prossamariti L., Filosa A., Rund D., Gamberini M.R., Cianciulli P., De Montalembert M., Gagliardotto F., Foster G., Grangè J.D., Cassarà F., Iacono A., Cappellini M.D., Brittenham G.M., Prati D., Pietrangelo A., Craxì A., Maggio A. Italian Society for the Study of Thalassemia an Haemoglobinopathies; Italian Association for the Study of the Liver, Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood 2010, 116(16):2875-2883. (Epub).
14. Hedeker D., Gibbons R.D. Longitudinal Data Analysis 2006, Hoboken Wiley, New Jersey.
15. Anderson L.J., Wonke B., Prescott E., Holden S., Walker J.M., Pennell D.J. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassemia. Lancet 2002, 360:516-520.
16. Maggio A., D'Amico G., Morabito A., Capra M., Ciaccio C., Cianciulli P., Di Gregorio F., Garozzo G., Malizia R., Magnani C., Quarta G., Rizzo M., D'Ascola D.G., Rizzo A., Midiri M. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cell Mol. Dis. 2002, 28(2):196-208.
17. Pepe A., Meloni A., Capra M., Cianciulli P., Prossomariti L., Malaventura C., Putti M.C., Lippi A., Romeo M.A., Bisconte M.G., Filosa A., Caruso V., Quarta A., Pitrolo L., Missere M., Midiri M., Rossi G., Positono V., Lombardi M., Maggio A. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica 2011, 96(1):41-47.
18. Pennell D.J., Berdoukas V., Karagiorgia M., Ladis V., Piga A., Aessopos A., Gotsis E.D., Tanner M.A., Smith G.C., Westwood M.A., Wonke B., Galanello R. Randomized controlled trial deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006, 107(9):3738-3744.
19. Borgna-Pignatti C., Cappellini M.D., De Stefano P., Del Vecchio G.C., Forni G.L., Gamberini M.R., Ghilardi R., Piga A., Romeo M.A., Zhao H., Cnaan A. Cardiac morbidity and mortality in deferoxamine or deferiprone treated patients with thalassemia major. Blood 2006, 107(9):3733-3737. (P).
20. Piga A., Gaglioti C., Fogliacco E., Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003, 88(5):489-496.
21. Maggio A., Vitrano A., Capra M., Cuccia L., Gagliardotto F., Filosa A., Magnano C., Rizzo M., Caruso V., Gerardi C., Argento C., Campisi S., Cantella F., Commendatore F., D'Ascola D.G., Fidone C., Ciancio A., Galati M.C., Giuffrida G., Giugno G., Lombardo T., Prossomariti L., Malizia R., Meo A., Roccamo G., Romeo M.A., Violi P., Cianciulli P., Rigano P. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomized clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cells Mol. Dis. 2009, 42(3):247-251.
22. Pennell D.J., Carpenter J.P., Roughton M., Cabantchik Z. On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure. J. Cardiovasc. Magn. Reson. 2011, 13:45-53.
23. Maggio A., Vitrano A., Calvaruso G., Barone R., Rigano P., Mancuso L., Cuccia L., Capra M., Pitrolo L., Prossomariti L., Filosa A., Caruso V., Gerardi C., Campisi S., Cianciulli P., Elfteriou A., Angastiniotis M., Hamza H., Telfer P., Walker J.M., Phrommintikul A., Chattipakorn N. Serial echocardiographic left ventricular ejection fraction measurements: a tool for detecting thalassemia major patients at risk of cardiac death. Blood Cells Mol. Dis. 2013, 50(4):241-246. (Epub).
24. Gao X., Qian M., Campian J.L., Marshall J., Zhou Z., Roberts A.M., Kang Y.J., Prabhu S.D., Sun X.F., Eaton J.W. Mitochondrial dysfunction may explain the cardiomyopathy of chronic iron overload. Free Radic. Biol. Med. 2010, 49:401-407.
25. Lesnefsky E.J., Moghaddas S., Tandler B., Kerner J., Hoppel C.L. Mitochondrial dysfunction in cardiac disease: ischemia-reperfusion, aging, and heart failure. J. Mol. Cell. Cardiol. 2001, 33:1065-1089.
26. Link G., Saada A., Pinson A., Konijn A.M., Hershko C. Mitochondrial respiratory enzymes are a major target of iron toxicity in rat heart cells. J. Lab. Clin. Med. 1998, 131:466-474.
27. Glickstein H., El R.B., Shvartsman M., Cabantchik Z.L. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood 2005, 106(9):3242-3250.
28. Link G., Konijn A.M., Hershko C. Cardioprotective effect of alpha-tocopherol, ascorbate, deferoxamine, and deferiprone: mitochondrial function in cultured, iron-loaded heart cells. J. Lab. Clin. Med. 1999, 133(2):179-188.